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Abstract
Based on the dry powder coating technology platform, this study aimed to develop
immediate release ginseng chewable tablets using the electrostatic powder coating technique
and sustained release amino acid pellets using the plasticizer powder coating technique. For
the immediate release ginseng chewable tablets, the content and types of tableting materials,
as well as coating materials, coating temperature, curing time and coating level, were
optimized. For the sustained release amino acid pellets, coating level and curing time, as well
as the composition of ethyl cellulose (EC), were optimized. In summary, these laboratory
studies provided new opportunities for additional potential commercial applications for dry
powder coating technology.
Keywords: Dry powder coating, ginseng chewable tablet, amino acid pellet
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Chapter 1

1

Introduction

1.1 Pharmaceutical coatings
Generally speaking, the production process of coated drugs can be seen in Figure 1.1. It is
usually divided into five parts, including mixing, drying, tableting, coating and final
packing.

Figure 1.1 The production process of coated drugs
Coatings are commonly used to make the surface of tablets smoother and in order to
enhance their appearance, make them resistant to harsh environment (prolonging their
shell life), or to achieve immediate release, sustained release and delayed release of the
active pharmaceutical ingredient (API) [1].
Among them, immediate release is typically used for veiling taste, identifying via coating
color (usually green can reduce the patient's anxiety and white can relieve pain), and
protecting the API from harm by external environment. Sustained release enables the API
to discharge over an extended amount of time thus delays the remedial impact. Delayed
release discharges the API at a set time rather than discharge quickly after oral
administration. All the previously mentioned purposes can be accomplished with various
coating materials.
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Currently, liquid coating technology is commercially used to coati solid dosage forms. In
general, for water-insoluble materials, a blend of polymers, colors and excipients are
dissolved in a proper organic solvent to form the solution. Water-soluble polymers can be
blended into a mixture with colors and excipients and be dissolved or dispersed in the
water directly. After drying, a dosage form may be sprayed with the solution to create a
uniform film on the surface.
However, evaporation of organic solvents or water occupies a large part of the total cost
of the coating process due to the requirement of heat. Furthermore, a treatment time of
hours or even several days is crucial for liquid-based coating technologies to obtain a
uniform and dry surface. Moreover, using organic solvents can increase the risk of
environmental pollution and explosive hazards. Lastly, in addition to the cost associated
with long processing time and energy cost for evaporation, the organic solvents
themselves bring additional costs to the coating process. [2]
New efforts have been made in recent years to overcome the drawbacks of liquid coating
technologies such as dry coating technology. Dry coating technologies can be categorized
as liquid-based or solid-based. Liquid-based methods include both hot-melt and
photocurable coating. Solid-based coating includes press coating, thermal adhesion
coating, plasticizer-assisted powder coating and electrostatic powder coating. Among
these mentioned technologies, dry coating is the most widely studied and has not yet been
explored. [3]
Specifically, for the electrostatic coating technology, an electrostatic interaction is
applied to promote the adhesion of polymers that are not easily film-formable. For this
coating method, negative and positive charges are introduced to the blended mixture and
the surface of the tablet and plasticizer is added to decrease the glass transition
temperature (Tg) of the coating materials. Plasticizer-assisted coating is used directly for
polymers that are not easily film-formable.
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1.2 Ginseng chewable tablets
Ginseng is a slow-growing plant with fleshy roots that has been used for over 2000 years.
Ginseng is believed to restore and enhance energy, making it one of the most popular
herbs. People even think ginseng is a panacea and possesses the ability of prolonging life.
The efficacy of ginseng was known before the 18th century, and the herb has had a long
history of research. [4] Recently, researchers have revisited the use of biochemistry and
molecular biology techniques to study ginseng pharmacology. Ginseng and its
ingredients have been attributed to anti-tumor and anti-stress. It is a herb with many
active ingredients, and there are numerous studies showing that ginseng does have a
beneficial effect in treating the conditions mentioned above. [5]
The active ingredients in most types of ginseng include: ginsenosides (shown in Figure
1.2 and which is considered as the main ingredient), polysaccharides, peptides,
polyacetylene alcohols, and fatty acids. [6] However, the amount of ginsenosides in
different types of ginseng varies widely (2-20%). [7]

Figure 1.2 The structure of one special ginsenoside
American ginseng has been primarily exported to Asia for its value and high level of
quality since the 18th century. Traditional methods of ginseng consumption include
stewing, boiling and steaming, but these three methods require a lot of time. Ginseng can
also be orally taken, but most people are uncomfortable with its bitter taste. A solution
proposed is to grind ginseng into fine powder (the diameter is less than 40um), add some
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sweetener to mask the bitterness, and press the mixed fine power into chewable tablets to
meet the needs of modern fast-paced people.
Chewable tablets usually contain a certain amount of active ingredients and excipients.
Excipients include binders to allow better adhesion of various raw material powders,
lubricants to complete the tableting process, and sweeteners to mask the unpleasant taste
of the material itself. In addition, the use of a polymer coating makes the surface
smoother and increases the resistance of the chewable tablets to the external environment.
Typically, there are two commonly used methods to granulate. Wet granulation uses a
liquid binder to agglomerate the mixed powder lightly, while dry granulation creates
pellets by compacting the mixed powder under a certain level of low pressure lightly.
Ginseng has a similar structure to sawdust which easily leads to the formation of mold in
the presence of water. For this reason, a dry granulation process is often chosen as the
method to granulate ginseng.
Since the ingredients in ginseng are often unpalatable, chewable tablets should be
flavored to be sweet or sour, giving off a cool sensation while chewing. For this reason,
the addition of mannitol is considered due to its sweet flavor and ability to easily absorb
heat in the mouth. Additionally, mannitol has excellent stability, mobility and
compressibility. Due to its lubricating properties, magnesium stearate is the most
commonly used lubricant to tablets for prevent ingredients from sticking to the equipment.
In addition, magnesium stearate is generally safe for human intake under the levels of
2500 mg/kg per day. Mannitol and magnesium stearate are believed to be appropriate
materials for the experiment.

1.3 Amino acid pellets
Amino acids are organic compounds that contain amino and carboxyl groups. Different
amino acids are different in the R group. Amino acids are the fundamental substances
that compose the proteins necessary for animal and human needs. In the form of proteins,
amino acids are the second largest component in the human body. Amino acids can exert
several effects through metabolism in the human body such as the synthesis of tissue
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proteins, conversion to ammonia, hormones, antibodies, creatine and other ammoniacontaining substances, conversion to carbohydrates and fats and oxidation to carbon
dioxide, water and urea, as well as energy generation. [8]
The first amino acid which is aspartic acid isolated from asparagus was found in 1806 by
French chemists Louis-Nicolas Vauquelin and Pierre Jean Robiquet. [9] The last amino
acid is threonine, which was discovered by William Cumming Rose in 1935. Rose also
defined the content of essential human amino acids. [10]
During the beginning of the amino acid industry, protein hydrolysis was often used to
hydrolyze raw materials such as feathers and pig blood into amino acids. Since the 1960s,
the industry has placed greater attention on microbial fermentation methods. Compared
with traditional protein hydrolysis methods, the cost of industrial fermentation methods is
greatly reduced; helping the amino acid industry develop rapidly. The application of
amino acids in the industry is mainly used in animal feed additives and food industries, as
well as in pharmaceuticals and cosmetics. [11]
In the food industry, a creative idea is to make certain amino acids into sustained-release
pellets to achieve certain effects within a certain time period. When people perform
intensive physical exercises, valine can provide additional energy to make the muscle
produce glucose and prevent weakness; isoleucine can promote the healing of bones and
damaged muscles; leucine and valine and isoleucine synergistically promotes muscle
recovery, with valine being the most efficient. Usually, athletes spend 2 to 3 hours of
intense physical exertion on sports such as football or basketball. However, on the second
day, they often experience muscle soreness. This situation is unideal for people today in
terms of both health and work. Therefore, three kinds of amino acids are used according
to a certain ratio of the mixture to make a complete release of sustained-release pellets
within 2 to 3 hours. This product can protect an athlete’s muscles during exercise and
reduce discomfort after physical activity.
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1.4 Objectives and contributions
The main purpose of this project is to explore the applications of dry powder coating
technology, including the following aspects:
First, to realize immediate release ginseng chewable tablets based on dry powder coating
technology with hydroxypropyl cellulose (HPC) as the coating materials.
Second, to realize sustained release amino acid pellets based on dry powder coating
technology with ethyl cellulose (EC) as the coating materials.
Thirdly, to optimize the processing conditions of dry powder coating including powder
formulation, curing time, and the ratio of plasticizer to powder to ensure product quality
while reducing overall cost.
Finally, these experimental results can be extended and provide new opportunities for
additional potential commercial applications for dry powder coating technology.
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Chapter 2

2

Literature Review

2.1 Types of drug release
Drug release profiles can be divided into three following types: immediate release
sustained release and delayed release. Immediate release is also known as conventional
release, both delayed release and sustained release can be called modified release.
The types of the drug release typically targets the stability and safety as well as the
therapeutic profile and efficiency. Three typical drug release profiles are shown in Figure
2.1.

Figure 2.1 Three types of drug release profiles

2.1.1 Immediate release
Immediate release is mostly applied to oral pharmaceutical products, such as tablets and
capsules that are aimed to release active ingredient immediately without altering the rate
of drug release after oral administration. Given that immediate-release oral
pharmaceutical products contain prodrugs, the absorption may be slower due to metabolic
or biochemical transformation by liver or intestinal metabolism. Alternatively, slow and
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gradual dissolution or selective absorption in the gastrointestinal tract cannot keep up
with the rate of drug release, which leads to delayed onset of action.

2.1.2 Sustained release
To achieve a better therapeutic effect, the release rate of the drug from tablets or capsules
should be at a predetermined rate in order to maintain a constant drug level. However,
some external factors such as pH will affect the drug release rate.
Sustained release, which is also known as extended release, refers to the system that
allows the drug to be released over an extended period of time to achieve a prolonged
therapeutic effect after oral administration by maintaining the level of drug in the blood
or target tissue. [12] Due to the more flexible formulation design, the route of
administration of oral sustained release systems has received more attention. There are
several important and interrelated variables such as the disease being treated, the
treatment time and the nature of the drug influencing the design of oral sustained release
system. If the release system can provide some control or be sustained in the time, space,
or both of the drug release rate in the human body, it is considered a sustained release
system. [13] Sustained release drug formulations can allow at least a two-fold reduction
in dose frequency compared to drugs that are presented as immediate (conventional)
release dosage forms [14].

2.1.3 Delayed release
The definition of delayed release is that the release of the active ingredient is at a set time
instead of immediately after oral administration. Usually, delayed release coating
prevents tablets passing through low-pH (1.5-3.5) environment (stomach) from being
destroyed by gastric juice due to high-pH (>6.5) environment (intestinal tract). However,
once the dosage form reaches the high-pH environment, the release occurs rapidly and
the profile is similar to the immediate release. [12]
Coated dosage forms such as enteric-coated aspirin are commonly used delayed release
products. [13]
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2.2 Coating materials
As stated before, the coating aims to enhance the appearance of the tablets or capsules
(such as making it smoother or colorful), providing the protecting in external
environments, and achieving functional control with three typical release.
Initially, sugar was used as the pharmaceutical coating material until the 1950s when it
was replaced by film coating technology. The main film coating materials are typically
semi-synthetic copolymers of cellulose derivatives and synthetic methacrylate polymers,
such as methyl cellulose (MC), ethyl cellulose (EC) and hydroxypropyl cellulose (HPC),
a cationic copolymer based on dimethyllaminoethyl methacrylate, butyl methacrylate,
and methyl methacrylate. [15]

2.2.1 Polymers for immediate release
Most of the polymers used for immediate release coatings are water-soluble, and their
rapid dissolution in water ensures the immediate release of active ingredients.
Hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC) and Eudragit®
E PO (EPO) are three examples of polymer materials for immediate release.
HPC (Fig. 2.2) is often used with HPMC, but their molecular weight is different, and the
degree of substitution between methoxy and hydroxypropoxy groups is different as well.
HPC and HPMC are cellulose ethers, some of its hydroxyl groups have been
hydroxypropylated to form propylene oxide groups. [16]
Both HPC and HPMC are widely used in the pharmaceutical field. However, HPC has a
stronger binding force than HPMC, which makes the film formed by HPC to have better
plasticity and stability. [17]
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Figure 2.2 The structure of HPC
Eudragit® E (Fig. 2.3) includes the series of Eudragit® E 100, Eudragit® E PO and
Eudragit® E 12.5. The series of Eudragit® E is essentially a cationic copolymer.
The ratio of dimethylaminoethyl methacrylate, butylmethacrylate, and methyl
methacrylate is 2:1:1 in Eudragit® E 100. Eudragit® E 100 is also the liquid form of
Eudragit® E PO. Eudragit® E 12.5 is a mixture of Eudragit® E 100, isopropyl alcohol and
acetone.

Figure 2.3 The structure of Eudragit® E
Along the main chain, monomers are distributed randomly. Based on a size-exclusion
chromatography (SEC) method, the average molar mass (MW) of the series of Eudragit®
E is approximately 47,000 g/mol. [17]

2.2.2 Polymers for sustained release
Polymers applied in sustained release are aimed at maintaining a consistent level of drug
in the blood or target tissue after oral administration. Ethyl cellulose (shown in Fig. 2.4)
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and Eudragit® RL and Eudragit® RS (shown in Fig. 2.5) are commonly used in the
sustained release. [12]
Ethyl cellulose has become a widely used film coating polymer for oral sustained release
dosage forms since 1958. The polymer was originally made into an organic solution, and
it was later developed into aqueous emulsion dispersions and powders. [18]
Ethyl cellulose is an ethyl ether of cellulose. Ethyl cellulose can be obtained with the
reaction of ethyl chloride and alkaline cellulose (treatment of the crude fiber with a lye).
As with most film coating polymers, ethyl cellulose also has various grades with different
molecular weights, each grade being expressed by its viscosity value. [19]

Figure 2.4 The structure of ethyl cellulose
Eudragit® RL and Eudragit® RS are acrylates and methacrylates, which have some
hydrophilicity because of the quaternary ammonium groups (trimethyl-ammonioethyl
methacrylate chloride) (shown in Fig.2.5). [20] They are insoluble in water but become
permeable and swelled in the presence of digestive fluid without the effect of pH. They
are generally used in matrix formulations for film coating of tables, capsules and pellets.
[21]
The content of quaternary ammonium groups is the only difference in the two polymers.
In Eudragit® RL, the molar ratio of quaternary ammonium groups to neutral methacylic
acid ester groups is 1:20. However, it is 1:40 in Eudragit® RS. Thus Eudragit® RL has a
higher permeable property compared with Eudragit® RS. [22]
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Figure 2.5 The structure of Eudragit® RL and Eudragit® RS

2.2.3 Polymers for delayed release
The most commonly used polymers for delayed release are cellulose-based and
mathacrylate-based polymers. These polymers protect the active ingredient from damage
in a low pH external environment such as the stomach (pH 2-3). Meanwhile, the
polymers can dissolve immediately in high pH zone, such as the small intestine with the
pH of 6.5-7, and the colon with the pH of 7.0-8.0. [23]
Currently, the series of Eudragit® including L100-55, S100 and L100 are the three
typical polymer powders mostly used for delayed release. Eudragit® L100-55 (shown in
Fig.8) is also named Acryl-EZE and dissolves above the pH of 5.5. L 100, (shown in Fig.
2.6), which dissolves above the pH of 6.0, and S 100, which dissolves at a pH level of
over 7.0, are anionic copolymers. In the series of L 100, the ratio of free carboxyl groups
to the ester groups is approximately 1:1. However, it is 1:2 in Eudragit® S 100. Along the
main chain, the monomers are distributed randomly. Based on the size-exclusion
chromatography method, the average weight molar mass (Mw) of the series of Eudragit®
including L100-55, S100 and L100 is approximately 125,000 g/mol. [24]
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Figure 2.6 The structure of (a) Eudragit® L 100 and (b) Eudragit® L 100-55 in low
pH (1-2)

2.2.4 Plasticizers
In general, a typical plasticizer is a water-insoluble material with low molecular weight
(200-1000g/mol). Plasticizers are used as a non-volatile additive to incorporate
themselves between/in the polymer chains, increasing the free volume to improve the
flexibility and processability of polymers by lowing the glass transition temperature (T g).
[25] The falling value of Tg compared with the original Tg can be used as a factor that
characterizes plasticization efficiency. [26]
In the pharmaceutical coating industry, triethyl citrate (TEC, shown in Fig. 2.7) and
polyethylene glycol 400 (PEG400) are most commonly used due to stable performance
and relatively low prices.

Figure 2.7 The structure of TEC
TEC is better combined particularly with immediate release materials and delayed release
materials, such as EPO, Eudragit® series including L 100-55, L 100 and S 100. PEG 400
shown in Fig. 2.8 is more suitable with sustained release materials such as Eudragit® RL
and Eudragit® RS. [27,28]

14

Figure 2.8 The structure of PEG 400
When incorporated between/in the polymer chains, plasticizers increase the separation of
polymer molecules, forming the free zone to improve the flexibility and processability by
decreasing elastic modulus, tensile strength and Tg. [29] This leads to the realization of
lower heat treatment. In addition, plasticizers increase the electrical conductivity to
attract more powder depositing on the surface of the tablets or pellets, thus increasing the
efficiency of powder materials in the electrostatic dry coating technique. [27,30]
Two key parameters will be considered when choosing a suitable plasticizer. One is the
compatibility with the polymer, which is that coating polymers should have high
solubility in the plasticizer. [31] The second is the plasticization efficiency, since only a
reasonable amount of plasticizer with polymer can form a uniform and continuous film.
An excessive amount plasticizer leads to the leakage of plasticizer on the surface of film
and cause it to become brittle. Ultimately, considering polymer compatibility and a
suitable plasticizer ratio is a critical process in film coating. [32]
Although traditional plasticizers are usually liquid, the concept of solid plasticizers is
now proposed as an alternative. Solid plasticizers act as auxiliary plasticizers and are
most typically used in conjunction with a primary liquid plasticizer. Their main role is to
promote the plasticization of polymer materials and to suppress the precipitation of the
primary plasticizer.
A typical solid plasticizer used in this experiment is lactose (Fig. 2.9). Lactose is a
disaccharide composed of galactose and glucose. Usually, milk contains 2 to 8 % total
weight of lactose. Lactose has good water solubility and a faint sweetness, so it is often
used in the food and pharmaceutical industry.
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Figure 2.9 The structure of lactose

2.3 Solvent-based coating
Solvent-based coating methods, including sugar coating, organic solvent coating and
aqueous-based coating are widely accepted and used in modern pharmaceutical coating
processes. The sugar coating pharmaceutical process was first invented in the United
States in 1856, which is still a widely used technology, although people have payed
attention to film coating technology since the 1950s. Due to its more environmentally
friendly properties, aqueous film coatings have replaced some organic solvent coatings.
[33]

2.3.1 Sugar coating
In sugar coating equipment, tablets or capsules are treated with sugar solution containing
pigments or certain functional ingredients, the degree of treatment is dependent on the
required coating level. The sugar coating industry is labor-intensive relative to film
coatings. Firstly, the sugar coating process requires many laborers to handle the multistep process. Secondly, there needs to be highly skilled laborers to properly perform the
operations of the process.
Several advantages are considered when choosing sugar coating. Sugar is a cheap and
easily available material and widely accepted by public, which can avoid regulatory
issues. Compared with film coating equipment, sugar coating equipment is less
complicated.
A downside of sugar coating, however, is that tablet cores need to be softer than that in
film coating. In addition, a whole sugar coating process usually will last for several days.
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Thus, today's pharmaceutical industry has suspended the development of sugar coating
process due to its long-time treatment and labor force.

2.3.2 Organic coating
Like the sugar coating, the color or some of the functional ingredients are dissolved in the
organic solution, and the tablets are dried after the solution is sprayed on the surface to
obtain a dry and uniform film. The schematic of organic solvent coating can be seen in
Fig. 2.10. Conversely, unlike sugar coating, the use of an organic solvent coating process
reduces the requirements of labor and the level of operation when compared to the sugar
coating process. [34]

Figure 2.10 The mechanism of organic solvent coating
Organic solvent coating is still the primary choice for the coating industry due to the
stability and maturity of the technology. However, it still has several disadvantages. First,
the organic solvent coating needs to be dried to obtain the desired film. This process
requires a lot of time and energy, which leads to an increase in cost, and an increase in
temperature which, concordantly, increases the risks associated with the inactivation of
the active ingredients. Second, achieving different release profiles often requires multiple
sprayings, which makes the process more complicated. A non-uniform coating results in
a decrease in stability and efficacy of the production. Due to these shortcomings, the
solvent-free coating technology has received more and more attention. [34]

2.3.3 Aqueous coating
The study of water-based coating technology began in the early 1970s with the
development and utilization of a series of water-based coating materials. [35] The rapid
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development of fluidized-beds, high-efficiency coating pans and other technical
equipment also promoted the development of this technology. For the stability of the film
and coating uniformity, water dispersion materials are generally diluted by the principle
of compatibility to reduce the solid content to 16% from 24% before use. To change the
release rate and improve certain properties of aqueous dispersions, the amounts of
excipients such as plasticizers, anti-adherents, porogens, and the drug channels need
regulated. [36]
Alginic acid propylene glycol can be added to the coating material to study the stability
of the membrane to increase the stability. Aqueous dispersion formulation can be made
by biological materials, such as nano-ploymers.. As shown in Fig. 2.11, the dispersion
and water were deposited on the drug surface during the formation of the film. After the
water begins to evaporate, the polymer particles begin to compact and deform. Finally,
after the water is completely evaporated, the polymer particles are interconnected and
form a film. [32]

Figure 2.11 The mechanism of aqueous coating
Water coating technology began because of people’s increasing level of attention to
environmental protection and the rise of organic solvent price. Substituting water for
organic solvents can avoid organic solvent emission to the outside during the coating
process, avoid the occurrence of flammable and explosive, reduce the cost of itself and
investment of the recycle system, and eliminate the damage to the operator caused by
organic solvents. [33] However, due to its full-water properties, unique film formation
mechanism and other factors, there are also certain problems in practical applications.
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Some polymers have poor dispersion in water, which can lead to clogging of spray
nozzles. Furthermore, if the active ingredient is sensitive to moisture, residual moisture in
the film can cause inactivation of the active ingredient. [37]

2.4 Dry coating
In view of some inevitable drawbacks in solvent coating process, today’s pharmaceutical
coating industry has given rise to several dry/solvenless coating technologies. Time in
both drying and spraying and cost due to the evaporation of solution decrease
significantly when using dry coating technologies.
Dry coating techniques are generally split into two types. One is liquid-based techniques,
including hot-melt coating and photocurable coating. The other one includes press
coating, thermal adhesion coating, plasticizer-assisted powder coating and electrostatic
powder coating, which is known as solid-based techniques.

2.4.1 Liquid-based coating
Hot-melt coating
The hot-melt coating is mainly used in the pharmaceutical coating industry to improve
the stability of the drug to the external environment, mask the taste of the drug itself and
realize a sustained release. [38] As its name suggests, a typical hot-melt coating consists
of four steps: preheating substances, heating the desired coating material to a molten state,
then spraying it onto the surface of the substance, and cooling under controlled conditions
to obtain a uniform film. This process usually uses a fluidized bed or a rotating pan to
produce coated pellets. [39]
Because of the need of both melting and cooling processes, temperature is the core
parameter in the hot-melt coating process and need to be tightly controlled in any
equipment. During the spraying process, the temperature of the material needs to be kept
40-60℃ higher than the melting temperature of the material. [40] Therefore, the material
must be heated in the pipe from the reservoir to the nozzle to avoid cooling and clogging.
[41] The nozzle also needs to be specially designed, such as a triaxial nozzle, shown in
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Fig. 2.12, to prevent the deposition of droplets in the nozzle. The hot melt material must
have a low melting point, stability in both physical and chemical states, good flowability
to be sprayed easily. Fatty acids, partially hydrogenated vegetable oils (mostly palm oil,
but also soybean oil and cottonseed oil), paraffin wax and polyethylene glycol are
common hot-melt coating materials. [42]

Figure 2.12 The actual device of nozzle for hot-melt coating [42]
(a) Melted coating material. (b) Nebulizing airflow. (c) Heated compressed air.
The hot-melt coating is very effective for small dosage applications, such as small
particles and pellets. At the same time, this technique saves time if a suitable low melting
coating polymer is available. However, many cores with active ingredients cannot
tolerate the temperature at which the material is melted, which can lead to inactivation or
decomposition of active ingredients. In addition, so far, there are not many materials
available for selection, which further restricts the production of high-quality coated
products produced by the hot-melt coating process.
Photocurable coating
The photocurable coating method provides a chemical method to achieve the coating
layers. That is, using a radical polymerization reaction in the presence of a
photosensitizer and at a lower temperature to form a mutual indirect network and then
turns into a film in a very short time. [42]
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The photocurable coating process needs to be equipped with a light source that can
provide ultraviolet-visible light and a nitrogen purging system to avoid damaging the
formed film due to the presence of oxygen after the reaction. Wang and Bogner
introduced a dry photocurable coating method into the pharmaceutical field, where a
stable film is obtained with nonpareil beads under conditions similar to conventional pan
coating. [43]
The photocuring coating method is characterized by low operating temperature and short
processing time compared to other dry coating methods, and therefore is very suitable for
photosensitive materials. However, due to toxicological limitations, photocuring coating
materials are generally not recognized as safe, limiting their application in the
pharmaceutical field. [44,45]

2.4.2 Solid-based coating
Press coating
The press coating technique (or compression technique) utilizes compressive force to
achieve a coating layer. First, the tableting mold is filled halfway with the coating
material powder. Afterwards, the core is placed into the center of the tablet, filling the
remaining half of the coating material powder into the mold and compresses to obtain a
film with a certain level of thickness. The press-coated tablet can be seen in Fig. 2.13. [45]

Figure 2.13 The press-coated tablet
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In press coating, the outer film has a great influence on the mechanical strength and
stability of the product. At the same time, the position of the inner core needs to be
exactly in the center of the product. [46,47] Therefore, as an improved method, a one-step
manufacturing method is proposed based on an equipment with special design. In this
process, the product can be used for delayed release, and adjustments to the thickness of
the film can control the release profile. [48]
Most of the press coating materials are selected to have hydrophilic and expandable
polymers, such as cellulose derivatives, including hydroxypropyl methylcellulose
(HPMC), hydroxy ethlcellulose (HEC) and hydroxypropyl cellulose (HPC). [49,50] In
addition, these polymers are degradable and of low cost.
However, the compression coating is limited by the thickness of the coating, and there are
less active ingredients that can be utilized in this technology in comparison with other dry
coating technologies. This reduces the production efficiency, especially for some smaller
particles and pellets.
Thermal adhesion powder coating
Thermal adhesion powder coating (or heat-drying coating) utilizes thermal reaction to
achieve a powder coating film. The coating powder is a mixture of a polymer, which had
been plasticized beforehand and then milled in a room or lower temperature after the hot
melt extrusion process, and talc powder (added to prevent sticking between powders and
powders and walls). Therefore, the thermal properties of the coating powder are of great
importance in the thermal adhesion powder coating technology. [51]
In a typical thermal adhesion coating process, the plasticizer content can reach up to 40%
of the total weight, and requires a long curing period to ensure the film's uniformity and
stability. The application of the thermal adhesion coating described in the literature
mostly uses an acrylic polymer and a modified rotating pan. The designed rotating pan
adds a centrally located powder feeder and an infrared heating device at the top. The
outline of solid-based coating techniques can be seen in Fig 2.14. [45,52]
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Thermal adhesion powder coating

Plasticizer-assisted powder coating

Electrostatic powder coating

Figure 2.14 The outline of solid-based coating techniques
Plasticizer-assisted powder coating
In the plasticizer-assisted powder coating technique, plasticizers and powders are added
simultaneously or alternately from two different feeders, obtaining a uniform film after a
certain period of curing. A typical device is a traditional rotating pan or a fluidized bed
equipped with nozzles, or a three-way nozzle inserted into the device to transport liquids
and powders. [53,54]
The main purpose of the plasticizer-assisted powder coating is to reduce the glass
transition temperature (Tg) of the coating material. The plasticizer and coating polymer
are combined to increase the free volume within the polymer molecular, resulting in a
glass transition temperature lower than the curing temperature. This is also a precondition
for forming a film. Due to its performing operation at a lower temperature, the active
ingredients of the drug are protected. [55,56]
Triethyl citrate (TEC), polyethylene glycol 400 (PEG400) and acetylated monoglycerides
(AMG) or their mixtures are commonly used as liquid plasticizers. [57] However, some
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plasticizers may only be effective in a mixture with certain polymers. While the
plasticizer-assisted powder coating technique is not specifically required for the coating
substance, as it can be large tablets or small particles, a rotating pan is generally suitable
for large tablets and a fluidized bed is used for small particles to avoid the adhesion
between particles and between particles and walls. This technology has been applied to
achieve immediate release, sustained release and delayed release. [58-60]
The control of the amount of plasticizer and a higher coating level presents certain
drawbacks to this technology. The addition of too much plasticizer can result in adhesion
between particles and between particles and walls, and the addition of too little plasticizer
can cause an uneven film. Moreover, when compared to liquid coating, this technique
usually requires a higher level of coating to achieve the same effect.
Electrostatic powder coating
Electrostatic powder coating has become very mature in the metal surface treatment
industry, and an improved plasticizer-electrostatic-thermal powder coating has begun to
be applied to pharmaceutical coating industry. [61] As its name suggests, plasticizers are
used to lower the glass transition temperature (Tg) and increase the conductivity of the
tablets or pellets. Electrostatic force is used to increase force between the powder and the
coating substance, which is usually achieved by applying negative electrons to the
coating material. The rotating pan is grounded and equipped with an electrostatic gun.
After the coating materials are deposited onto the solid dosage surface, the electrons are
released to the ground through the grounded rotating pan, and the powder forms a
uniform film after a certain time of thermal reaction. [62]
In general, the process begins with the solid dosage form preheated to a target
temperature at a low speed in a rotating coating pan. Next, at a higher rotational speed, a
certain amount of plasticizer is evenly and discretely sprayed onto the solid dosage
surface, followed by amount of mixed powder sprayed from an electrostatic gun. The
rotating speed is reduced to allow the solids to form a uniform film at a certain
temperature and time. In general, achieving a stable and uniform film requires repeating
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this process many times. This technique has been successfully applied to control
immediate release, sustained release and delayed release. [63]
Electrostatic powder coating does not use organic solvents, which avoids the pollution
and the cost of evaporating associated with the solvent. At the same time, the
disappearance of water makes this technology applicable to water-sensitive materials.
However, this technology still has some limitations due to the precondition of static
electricity, and coating substances with low-conductivity being inefficient.
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Chapter 3

3

Materials and methods

3.1 Materials
3.1.1 Ginseng powder
Ginseng powder was provided by Mary Ginseng House. (Canada).

3.1.2 Amino acid pellets
The amino acid pellets were donated from MERRIN (Ningbo) Biotechnology Co., Ltd.
The composition of the amino acid pellets can be seen in Table 3.1.
Table 3.1 The composition of the amino acid pellets
Composition

% by weight

leucine

45%~55%

isoleucine

22.5%~27.5%

valine

22.5~27.5%

hypromellose (HPMC)

max 5%

3.1.3 Coating and tableting powders
Eudragit® E PO and Colloidal silicon dioxide (AEROSIL® 200 Pharma) were provided
by Evonik

Degussa

Corporation

(Germany).

Magnesium

stearate was

from

GlaxoSmithKline (UK). HPC was from Avantor Performance Material, Inc. (US). Talc
powder was from Bulk Pharmaceutical Chemical. (US). Mannitol (PEARLITOL® 100SD)
and sorbitol powder (NEOSORB® P110) were provided by ROQUETTE, Inc. (US).
Copovidone (PLASDONE® S-630) was provided by ISP TECHNOLOGIES, Inc. (US).
EC was donated by Colorcon. Inc. Lactose was from Foremost Farms USA Cooperative.
Yellow-6 and lake brilliant blue were brought from DRAGONI. Inc. (China).
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3.1.4 Plasticizers
Polyethylene glycol 400 (PEG 400) was donated by Acros Organics. Inc. (US). Triethyl
citrate (TEC) was from Alfa Aesar. Inc. (US).

3.2 Particle size reduction and analysis
When the powders are manufactured, they are cooled, then the large pieces are grounded,
and finally sieved to the powder with a specific particle size required by the manufacturer.
In general, fine particles facilitate jetting by the spray gun and fluidization in the
fluidized bed. In addition, smaller particles have more filled voids on the surface of the
coating, making the resulting film denser and more uniform. If the particles are too large,
aside from affecting the compactness of the film, fine spots will be formed on the surface
of the drug, thus affecting the appearance.
Choosing the right particle size to achieve a dense and uniform film during the coating
process is crucial. However, many of the materials obtained from suppliers do not
precisely match specific needs. In this frequent case, the particles need to be grounded
and subjected to ultrasonic sieving (HK Technologies Ultrasonics Rugby, United
Kingdom) before use.
After particle size reduction, particles will be characterized by a laser particle size
analyzer (TSI Corporation, Model 3603, Shoreview, MN, USA). Fraunhofer diffraction
theory is the basis of laser diffraction analysis. In the propagation of light, the front
waves are limited by apertures or particles that are equivalent to the wavelength scale,
and the diffraction is generated by spatially interfered the emission originated from the
elementary waves at the confined front wave. The spatial (angle) distribution of scattered
and diffracted light energy is related to the wavelength of the light wave and the
dimensions of the pore or particle. With a laser as the light source, the spatial (angle)
distribution of the diffracted and scattered light energy is only related to the particle
diameter after the light has a monochromatic beam with a certain wavelength. The
diffraction of the particle group determines how much each particle level corresponds to
the light energy obtained at each particular angle. The proportion of each specific light
energy in the total energy amount should reflect the abundance of each particle level.
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The volume mean diameter (D [4,3]) was used to describe the average particle size. The
calculation equation is as follows:

∑𝑛1 𝐷𝑖4 𝑉𝑖
D[4,3] = 𝑛 3
∑1 𝐷𝑖 𝑉𝑖
The average particle size of coating powders is shown in Table 3.2. Each size was
measured three times.
Table 3.2 The average particle size of coating powders
Coating powder

Average particle size, D [4,3] (μm)

Eudragit® E PO (EPO)

13.3

ethyl cellulose (EC)

21.6

talc

28.9

lactose

250.5

3.3 Angle of repose (AOR)
The angle of repose of the powder is the angle at which the powder can accumulate but
does not collapse. The density, shape and friction coefficient of the particles can be
reflected by the number of angle of repose.
The fixed funnel machine (Hosokawa micron corporation, JAP) was used to determine
the angle of repose. The ginseng mixed powder was poured through a funnel until a cone
was formed. The top of the funnel should be close to the cone as much as possible to
reduce the effect of falling particles. When the cone reached a predetermined height and
the side reached a predetermined width of the base, pouring of the powder was stopped.
The tangent of the height divided in half the width of the bottom of the cone results in the
angle of repose.
A diagram of the angle of repose can be seen in Figure 3.1. where r is the radius of the
cone base and θ is the angle.
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Figure 3.1 The diagram of the angle of repose

3.4 Tableting
Tableting is the process of compressing mixed powder into tablets of a certain size and
weight. During the tableting process, the lower punch partially extends into the die hole
and seals the bottom of the die hole. At the same time, a feeder is used to fill the die hole
with the drug, the excess drug is scraped off from the top of the die, and the upper punch
is pressed from the upper end to the die hole and descends a certain distance to compress
the powder into a piece. Afterwards, the upper punch is lifted from the hole and lower
punch upwards to eject the tablet out of the die hole to complete the pressing process.
Finally, the lower punch falls to its original position where it stays until the next tableting
cycle.
The tableting machines required for the tableting process include single punch tableting
machines and rotary tableting machines. Normally, the number of tablets is the main
factor for selecting a suitable tablet press. A single tableting machine can compress 60
tablets per minute, while a rotary tableting machine, the schematic of that can be seen in
Fig. 3.2, can compress 1,000 tablets per minute. In this experiment, the ginseng chewable
tablets (diameter is 1.5cm and thickness is 0.25cm) were prepared using a single-punch
tableting machine (GeXin motor factory, model G-7114, Shanghai, China) and the lactic
acid tablets (diameter is 0.7cm and thickness is 0.20cm) that assisted the ginseng
chewable tablets in the coating process used a rotary tableting machine (TianFan
pharmaceutical machinery factory, model ZP-8, Shanghai, China).
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Figure 3.2 The schematic of a rotary tableting machine

3.5 Scanning electron microscope (SEM)
Scanning electron microscopes use the secondary electron signal imaging to observe the
surface morphology of samples. The samples are scanned by a raster scan mode using an
extremely narrow electron beam. The number of secondary electrons that can be detected
depends on the morphology of the sample.
Through scanning the samples and collecting the emitted secondary electrons using a
special detector, the surfaces of the samples can be generated through the formation of
images. Since the secondary electrons are emitted very close to the sample surface, the
SEM can produce high resolution images of the sample surface, even displaying sample
details less than 1 nm.
In this experiment, An EMITECH K550 coater (Emitech Ltd., Ashford, UK) was
employed to coat the samples. After being coated, the samples were observed under a
scanning electron microscope at 5.0 kV (SEM, Hitachi S-2600N, Ontario, Canada).
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3.6 Hardness test
The hardness of the tablet plays an essential role in the quality control of the product.
High hardness tablets require the addition of more lubricants and compressible
substances to the tablet formulation, which reduces the active ingredient content. At the
same time, if the hardness is too great, the disintegration time of the tablet will be longer,
and the release curve will be affected. On the other hand, if the hardness of the tablets is
too low, the tablets will be more brittle, which will affect the subsequent coating process
and transportation of the tablets.
Hardness testing of tablets is a widely used laboratory testing method. A hardness test
machine (Tianjin GuoMing medicinal equipment Co., Ltd, model YD-1, China) was used.
Tablets are usually placed between two flat plates, one of which is connected to a
pressure sensor and the other is connected to a motor that provides a driving force. In the
hardness test, the motor drives one plate close to the other until the tablet breaks and the
pressure sensor records the hardness of the tablet. In general, the hardness of a 500mg
chewable tablet is about 60 N.

3.7 In-vitro drug release testing
In-vitro drug release tests of the coated samples were runed by the United States
Pharmacopeia (USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai,
China). For EPO-coated ginseng chewable tablets, the drug release medium is 900 ml of
pure water maintained at 37°C with a paddle rotating speed of 50 rpm. For the EC coated
amino acid pellets, the drug release medium is 1000 ml of pure water maintained at 37°C
with a paddle rotating speed of 50 rpm.
In this process, 10 ml of the sample was collected through a 10ml syringe over a certain
period of time, and 10 ml of fresh medium (pure water) was immediately supplemented.
After 10 ml of the sample was filtered, it was analyzed using a UV-Visible
spectrophotometer. The maximum absorption wavelength of the analyzed component in
the ginseng chewable tablet was 481nm, while it was 210 nm in the amino acid pellets by
measuring standards
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3.7.1 Standard curve
The drug dissolution profiles of ginseng chewable tablets and amino acid pellets can be
seen in Figures 3.3 and 3.4, respectively. The curve is used to determine the
concentration of the sample obtained from the dissolution test.
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Figure 3.3 Standard curve of ginseng chewable tablets
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Figure 3.4 Standard curve of amino acid pellets

3.7.2 UV-Vis spectrophotometer validation
After the creation of the standard curve of ginseng chewable tablets and amino acid
pellets, a precision test, accuracy test and a stability test are required for the acceptability
validation of the application of UV-vis spectrophotometer that is used for the
measurement and analysis of the drug release from ginseng chewable tablets and amino
acid pellets.
Precision test
Two solution samples of the ginseng chewable tablets and amino acid pellets were
prepared. These samples have a concentration lower than the maximum standard
concentration curve and were scanned. The input concentrations of the UV-VIS
spectrophotometer and known concentrations determined the standard error and precision
testing. When the standard error is less than 1%, this test is considered successful.
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Standard Error =

𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
< 1%
𝑀𝑒𝑎𝑛 𝑑𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛

Accuracy test
Configure three samples of high, medium, and low concentrations, and then scan each
sample. Within a certain confidence interval, the difference between the actual
concentration of each sample and the average number of the test is the accuracy test of
this sample.
Percentage Difference =

|𝑇𝑢𝑟𝑒 𝑣𝑎𝑙𝑢𝑒 − 𝑀𝑒𝑎𝑛 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑣𝑎𝑙𝑢𝑒|
∗ 100%
𝑇𝑟𝑢𝑒 𝑣𝑎𝑙𝑢𝑒

Stability test
In the stability test, known concentrations of ginseng chewable tablets and amino acid
pellets solution samples that are less than the maximum concentration of the standard
concentration curve were placed in a dissolution at 37°C. Samples were taken with a
10ml syringe for a certain of periods (0 hours, 1 hour, 2 hours, 6 hours, 12 hours), and
then subsequently scanned. Using the initial concentration as a base, if the difference
between the sample concentration at 12 hours and the base concentration is minimal, the
release may be deemed stable.
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Chapter 4

4

Electrostatic Powder Coating of Ginseng Chewable
Tablets

4.1 Apparatus and experimental procedures
4.1.1 Apparatus
The rotating coating pan designed by the research group was applied to the coating of
chewable ginseng tablets. The schematic diagram of the rotating coating pan can be seen
in Fig. 4.1. It consists of four parts: an incubator that guarantees a constant temperature
and even heating of the coating pan. A circular outer coating pan with an oval inside
(with a diameter of 12.8cm and a depth of 12.8cm) sits within the incubator. There are
four wavy prisms inside the pan. The irregular movement caused by the prism and ellipse
accelerates the tumbling of the tablets inside the pan, making the tablets coating more
uniform. In addition, the liquid plastic spray system includes a metering pump and an
atomizing nozzle. The powder coating apparatus includes an electrostatic generator at the
spray gun and a nozzle. The temperature of the entire system and the rotational speed of
the rotating coating pan can be well controlled.

Figure 4.1 The schematic of rotating coating pan for ginseng chewable tablets.
(A) Liquid plasticizer spraying system. (B) Rotating coating pan. (C) Electrostatic
spraying gun. (D) Powder feeder
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4.1.2 Experimental procedures
The process of coating the ginseng chewable tablets with a rotary coating pan is divided
into five steps, including: preparing the coating powder, preheating the tablets and
equipment, spraying the liquid plasticizer, spraying the coating material, and curing the
tablet film.
The first step is preparing the tablets coating materials. The coating material (Eudragit®
E PO or hydroxypropyl cellulose) is mixed with the additives (talc, color, colloidal
silicon dioxide and pigment) into a homogeneous formulation until there is no significant
agglomeration or color difference.
The second step is to place a certain amount of ginseng chewable tablets and placebo
tablets (total weight is 50g) in a rotating coating pan, set a temperature exceeding the
glass transition temperature, and rotate the coating pan at a slow speed.
The speed is then increased to avoid sticking of the tablets surface when spraying the
plasticizer and coating material. After spraying the plasticizer for a certain period, a
certain weight of coating material is sprayed immediately, and the rotating speed is then
lowered. These two steps are usually repeated multiple times every 10-20 minutes.
The curing step begins when sufficient coating material is attached to the tablet surface.
To prevent sticking, talc powder is usually added, and the ginseng powder can also be
added to make ginseng chewable tablets full of ginseng taste. The rotation speed is
decreased and the temperature is kept stable. The curing process generally takes three
hours.

4.2 Optimization
The appearance of perfect immediate ginseng chewable tablets is shown in Figure 4.2.
For the core of ginseng chewable tablets, the tableting formulation was 40% ginseng
powder, 58% mannitol and 2% magnesium stearate. For the coating process, HPC was
used as the coating material, PEG 400 was selected as the plasticizer, the coating process
was carried out at 50 °C, the curing time was 3 h, and the ideal coating level was 2%.
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Figure 4.2 The appearance of coated ginseng chewable tablets production

4.2.1 Effects of tableting
According to the provisions of the Chinese National Pharmacopoeia (CNP), the amount
of ginseng per person per day should not exceed 3g. From the perspective of commercial
products, each tablet should be 500mg in size and contain 40% ginseng content.
Additives that may be used include sorbitol, mannitol, color, copovidone, colloidal
silicon dioxide, and magnesium stearate. In the tableting process, the empirical amount of
magnesium stearate is 0.5-2%, copovidone is 0-3%, and colloidal silicon dioxide is 1%.
The preliminary tableting formulation is shown in the Table 4.1.
Table 4.1 Empirical and preliminary tableting formulation for ginseng chewable
tablets
Empirical composition
Preliminary composition
Formulation
(wt%)
(wt%)
ginseng powder

40%

mannitol
sorbitol
magnesium stearate
copovidone
colloidal silicon dioxide

40%
35%

Total 52%-58.5%

20.5%

0.5-2%

1%

0-5%

2.5%

1%

1%
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Hardness
As mentioned before, the appropriate hardness is crucial for the subsequent coating
process. For ginseng chewable tablets, a hardness level too high can make the chewing
process very painful, thus affecting the taste. While a hardness level too low causes the
tablet to be broken during the coating process. The ideal hardness is 60 N. The tablet
formulation was modified to obtain a suitable tablet hardness. Note that both mannitol
and sorbitol are sweeteners and their effects are similar, but overbearing amount of
sorbitol can lead to diarrhea and digestive disturbances, so tablet hardness with different
sorbitol content was tested. Three tablets were used for each hardness test and the
average was taken as data.
The content of ginseng powder was 40%, magnesium stearate was 1%, copovidone was
2.5%, colloidal silicon dioxide was 1%, and the sum of mannitol and sorbitol was 55.5%.
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Figure 4.3 The effect of sorbitol content on hardness
From the Fig. 4.3 we can see that the content of sorbitol has little relationship with the
hardness. Under the premise of food safety, mannitol will be used as sweetener of
ginseng chewable tablets.
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By improving the sweetener formulation, the chewable tablet hardness is still much
greater than the target hardness. Because copovidone functions as a binder, it has the
function of increasing the compressibility of the tablet and increasing the hardness. As a
result, chewable tablets containing different levels of copovidone were used to test the
hardness. Three tablets were used for each hardness test and the average was taken as the
data.
The copovidone content was 0-5%, therefore the difference between the maximum data
and the minimum data was 5%. Compared to the low content of other additives
(magnesium stearate was 1%, colloidal silicon dioxide was 1%) and the fixed content of
ginseng powder (40%), the content of mannitol was higher, thus the error was relatively
stable. The total content of mannitol and copovidone was 58% at a ginseng powder
content of 40%. The effect of plasdone-S630 content on hardness can be seen in Fig. 4.4.
140

Hardness (N)

120

100

80

60
0

1

2
3
4
5
Plasdone-630 Content (wt%)

6

Figure 4.4 The effect of plasdone-S630 content on hardness
Higher copovidone content significantly increases the hardness of the tablet, so if the
tablet meets other requirements, copovidone can be removed from the formula.
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Lubricity
Tablets must have sufficient lubricity to meet tableting needs. Magnesium stearate and
colloidal silicon dioxide are all lubricants in the formulation, but colloidal silicon dioxide
can be suspended in air. If it is not handled properly, it will cause harm to the
experimenter. In addition, the price of colloidal silicon dioxide is much higher than that
of magnesium stearate, which is an extremely important element in industrial production.
Therefore, the formulation of magnesium stearate and colloidal silicon dioxide also needs
to be improved.
The way to characterize lubricity can be the through measurement of the angle of repose.
However, each test required the use of 60 g sample, which would undoubtedly greatly
increase the cost of the experiment. If the powder composing a tablet had poor lubricating
properties, then vertical rubbing marks would form on the sides of the tablet. Therefore,
in this experiment, the lubricating performance could be represented by the number of
traces. If the lubricating performance was poor and could not be compressed into tablets,
it was indicated by a cross (X). The result can be seen in Tablet 4.2.
40% of the formula was ginseng powder, and the total weight of sweetener, magnesium
stearate, and colloidal silicon dioxide was 60%.
Table 4.2 The number of trace with different magnesium stearate (raws) and
colloidal silicon dioxide contents (columns)
0%
0.5%
1%
1.5%
2%
0%

X

X

3

2

0

0.5%

X

X

3

2

0

1%

X

X

3

0

0

With 2% magnesium stearate, the mixed powder had good lubricity. At the same time,
similar result was obtained when 1.5% of magnesium stearate was mixed with 1% of
colloidal silicon dioxide. However, in view of the price of colloidal silicon dioxide which
is far greater than that of magnesium stearate, in addition to taking the importance of cost
in industrial process into account, 2% magnesium stearate was establish as the best
choice.
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Angle of repose
Experiments had shown that the average angle of repose of the powder with 40% of
ginseng, 58% of mannitol and 2% of magnesium stearate was 42.67°. Shown in Table 4.3.
The coefficient of static friction (μs) of this mixed powder was 0.9218 (tan θ≈μs).
Table 4.3 The result of angle of repose (40% of ginseng powder, 58% of mannitol
and 2% of magnesium stearate)
Number
1
2
3
Angle of Repose

42.3°

Average

42.8°

43.2°

42.67°

tan 42.67°= 0.9218

4.2.2 Effects of polymer
Both hydroxypropyl cellulose (HPC) and Eudragit® E PO (EPO) are commonly used as
immediate release materials. When comparing the two materials, it is seen that the film
formed by EPO is denser than the membrane formed by HPC. However, the operating
conditions of EPO are more complicated than that of HPC, and the amount of plasticizer
and the plasticizer-coating material ratio need to be controlled more precisely.
In addition, the EPO is much expensive than HPC. Because this experiment hopes to
make a product that can be applied, the price factor cannot be ignored. HPC was used as
an experimental coating material.

4.2.3 Effects of temperature
Although the treatment temperature can meet the requirements as long as the glass
transition temperature of the film is satisfied, it is still important to select the appropriate
processing temperature. A temperature too low will make the film less uniform and
increase the curing time, whereas one too high will affect the film fluidity and make the
tablet sticky.
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HPC was the coating materials and the coating temperature were 50 and 60°C. The ratio
of the weight of the coating powder to the weight of the plasticizer and the coating levels
are compared. The ratio of the weight of the plasticizer and the weight of the coating
powder can be used to characterize the bonding potential of the tablet. 0.2 is considered
an ideal value. The coating level is the ratio of the weight gain of the tablet during the
coating process and the tablet itself.
A certain weight of ginseng chewable tablets (5 tablets, each weighed 0.5 g) were mixed
with 47.5 g of placebo tablets. The tablets were preheated to reach the target temperature,
and subsequently coated with HPC and PEG 400. The final curing time was three hours
until a smooth film was obtained. The result can be seen in Fig. 4.5.
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Figure 4.5 The effect of temperature on bonding potential
In comparison to a higher temperature (60°C), a lower temperature ensured that the
materials were in good condition. Therefore, the ginseng chewable tablet coating process
was completed at 50°C.
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4.2.4 Effects of curing time
The coating material of ginseng chewable tablets is HPC, which is a thermoplastic
polymer and, thus, needs to be cured at a temperature exceeding the glass transition
temperature for a certain period.
An SEM of ginseng chewable tablets with different curing times (1,2 and 3h) can be seen
in Figure 4.6.

(B)

(A)

(C)

Figure 4.6 SEM of HPC coated ginseng chewable tablets with different curing time
(coating level: 3%). (A) 1h, (B) 2h, (C) 3h
The surface of the ginseng chewable tablet with only an hour of curing time was very
rough, as some large powder particles can be observed. The ginseng chewable film with
two hours of curing was relatively smooth, but had some visible bulges. After three hours
of curing, the ginseng chewable film became very uniform. In the three figures, the
surface of the film had some pores. Because it is immediate release coating, the influence
of pores was negligible compared to the properties of the material itself.
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4.2.5 Effects of coating level
As mentioned above, the ideal formulation can be seen in Table 4.4, and the ideal
operating conditions are shown in Table 4.5.
Table 4.4 A selected formulation of ginseng chewable tablets
Formulation

Composition (wt%)

ginseng powder

40%

mannitol

58%

magnesium stearate

2%

Table 4.5 A select operating conditions for ginseng chewable tablets
Condition
polymer
plasticizer

Characterize
hydroxypropyl methylcellulose (HPMC)
polyethylene glycol 400 (PEG400)
50℃

temperature
curving powder

talc + ginseng powder

curving time

3h

Film formation is accomplished by the deformation and flow of the coating material.
SEM was used to observe the relationship between coating levels and film formation.
Four different coating levels were used for the study, which could be seen in Fig. 4.7.

(A)

(B)
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(C)

(D)

Figure 4.7 SEM of HPC coated ginseng chewable tablets with different coating
levels (curing time: 3h). (A) 0%, (B) 1.5%, (C) 2%, (D) 3%
The surface of the ginseng chewable tablets without a coating process was very rough.
Without the protection of the film, and the ginseng chewable tablets were easily worn
during the transportation process and collided with each other, resulting in changes to the
appearance. The ginseng chewable tablets with a coating level of 1.5% had a film on the
surface, but they were not fine enough and some independent particles could be seen. The
films of ginseng chewable tablets with coating levels of 2% and 3% were very uniform,
and it was difficult to see the pores, which was essential for the tablet’s resistance to the
external environment.
As an immediate release ginseng chewable tablet, there is currently no document defining
how to characterize the chewing process. Therefore, chewable tablets with different
coating level were divided into four pieces to simulated human chewing behavior. To
facilitate the detection of dissolution, 2% of the water-soluble pigment was added to the
formulation of ginseng chewable tablets while reducing the mannitol content by 2%. The
results showed that the ginseng chewable tablets with 2% color did not differ from the
original ginseng chewable tablet in terms of hardness and selectivity to the coating
material.
The ginseng chewable tablets were placed in 900 mL of water at a constant temperature
of 37°C with a stirring rate of 50 rpm . The dissolution results can be seen in Figure 4.8.
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Figure 4.8 The effect of coating level on release time (curing time: 3h)
Evidently, there was no significant difference in the duration of the ginseng chewable
tablets of the three different coating levels. If no other factors are taken into consideration,
ginseng chewable tablets with 1.5% coating level is optimal use for production.
Coatings of ginseng chewable tablets increase the resistance of the tablets to the external
environment, such as the wear due to collisions. Therefore, different coating levels of
ginseng chewable tablets were placed in a small bottle (10cm in length and 3cm in
diameter), each bottle held 5 pieces of tablets, the bottle was then rocked up and down at
a frequency of 60 times per minute for 5 mins, and the wear rate was examined. The wear
rate is the ratio of the reduced mass of chewable tablets to the original mass. The greater
the wear rate, the more susceptible the tablet was during a collision. Three trails were
performed for each coating level and the average was taken. The effect of coating level
on wear rate could be seen in Table 4.6.
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Table 4.6 The effect of coating level on wear rate for ginseng chewable tablets
Coating level (%)

Wear rate after 5 mins (%)

0

3.27

1.5

0.31

2

0

3

0

The ginseng chewable tablets with 2% and 3% coating level did not wear within five
minutes, but the ginseng chewable tablets at 1.5% coating level wore 0.31% within the
same time. Although this figure is much smaller than the 3.27% without the coating, in
view of the longer duration of transportation, 2% or 3% coating levels will be selected for
maximizing the appearance of the goods.
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Chapter 5

5

Plasticizer-assisted Powder Coating of Amino Acid
Pellets

5.1 Apparatus and experimental procedures
5.1.1 Apparatus
Coating pans suitable for specific amino acids pellets are similar to coating pans for
ginseng chewing tablets. A schematic diagram of the rotating coating pan can be seen in
Fig. 5.1. As described above, a large incubator is thermostatic, where outside of the
coating pan is a circle with a diameter of 12.8 cm and a depth of 12.8 cm. There are four
prisms inside the coating pan. The irregular movement of the coating pan promotes the
rolling of particles, making the coated film more uniform. Due to the small weight of the
amino acid pellets, it is necessary to avoid the effects of gas as much as possible. The
liquid plasticizer spray system includes a metering pump and an atomizing nozzle that
requires the participation of gas. To avoid the use of a gas, the powder feed is handpoured as the specific surface area of the amino acid particles is large enough, and the
distribution of the powder after rolling in the particles is relatively even. In addition, there
is a cover on the outside of the rotating coating pan to prevent pellets from flying out of
the pan when the plasticizer is sprayed.

Figure 5.1 The schematic of rotating coating pan for amino acid pellets
(A) Liquid plasticizer spraying system. (B) Rotating coating pan.
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5.1.2 Experimental procedures
Just as the process of coating the ginseng chewing tablets, the preparation of coating
amino acid pellets also requires five steps—preparing the coating powder, preheating the
pellets and equipment, spraying the liquid plasticizer, spraying the powder, and curing.
The first step is to prepare the coating powder. Ethyl cellulose (EC) was selected as a
sustained release material. The addition of lactose which was the solid plasticizer made
the film denser and reduced the amount of liquid plasticizer. The addition of talc reduced
the adhesion between the particles.
The second step was to place 50 g of amino acid pellets into the rotating coating pan, set
the temperature above the glass transition temperature, and pre-heated at a lower rotation
speed.
The speed was then increased to avoid tablet surface adhesion when spraying plasticizers
and coating powders. Plasticizer (triethyl citrate (TEC)) was sprayed for a period of time
immediately followed by the spraying of a certain amount of powder and a reduction of
speed. These two steps usually need to be repeated several times every 10-20 minutes.
The curing step begins when a sufficient amount of coating material has adhered to the
pellets surface. To prevent adhesions, talc powder was added. The curing process usually
took three hours.

5.2 Optimization
From the cost perspective, the total ethyl cellulose (EC) content need to be reduced to 6%
weight on the pellets, the release time of amino acid particles can be up to 2 to 3 hours
and the coating film is sufficiently uniform. The EC content is affected by the coating
level and the proportion of EC in the powder material. Therefore, the optimization
process of the amino acid pellets includes, optimizing of the coating level and the
formulation, and under appropriate conditions, further optimization of the other factors.
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The release profile of a successful EC coated sustained release amino acid pellet is shown
in Figure 5.2. The formulation of the coating powder is 20% EC, 50% talc and 30%
lactose. The curing time is 3 hours and coating level is 30%.
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Figure 5.2 The release profile of EC coated sustained amino acid pellets product
(Coating powder formulation: 20% EC, 50% talc and 30% lactose.
Coating level: 30%. Curing time: 3h)

5.2.1 Effects of coating level
Commonly used coating materials are mixtures of EC, lactose and talc in a certain
proportion. EC is the key polymer for film formation. Lactose is a solid plasticizer that
reduces the amount of liquid plasticizer and inhibits the deposition of the main plasticizer.
Talc can significantly reduce the adhesion between particles themselves and between
particles and walls. Usually, in an ideal formulation, the weight ratio of talc to lactose is
between 1:2 and 1:3.
By adjusting the amount of plasticizer used and the amount of coating powder used, it
was ensured that the particles did not stick together during the coating process and the
particles were sufficiently moist.
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The release profiles of the amino acid granules for the three different formulas (see Table
5.1) and the different coating levels can be seen in Figure 5.3.
Table 5.1 The coating powder formulation for different series of amino acid pellets
Series

EC

Lactose

Talc

1

80%

15%

5%

2

60%

25%

15%

3

40%

40%

20%

500
EC=80%

Release time (min)

400

EC=60%
EC=40%

300
200
100
0
0

10

20
30
Coating level (%)

40

50

Figure 5.3 The effect of coating level on release time with different EC content.
(Curing time: 3h)
Higher coating levels tend to lead to longer release times. If the weight of the raw
material of amino acid pellets is constant, achieving a higher coating level requires more
plasticizer, more steps, and a longer curing time between each step. Therefore, the
formed film will be more uniform to some extent. The SEM images of amino acid pellets
with different coating levels could be seen in Figure 5.4.
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(B)

(A)

(C)

Figure 5.4 SEM of EC coated amino acid pellets with different coating level
(Coating powder formulation: 40% EC, 20% talc and 40% lactose. Curing time: 3h).
(A) 17.04%, (B) 19.17%, (C)27.95%
The film with 17.04% coating level had some pores and the surface of the film was
uneven. The film with 19.17% coating level was relatively uniform, but there were still
some pores. However, the film at 27.95% coating level was very uniform and it was
difficult to see the pores. The release time of these three samples were 105 minutes, 135
minutes and 400 minutes, respectively.
In general, the coating level and the release time were exponential, and a higher coating
level would result in a longer release time. For the release profiles that met the
requirement of 120~180 minutes, coating level could be as low as 18% for a powder
containing 60% EC by weight, and about 27% for a powder containing 40% EC by
weight. For the powder containing 80% by weight of EC, this value needed to reach 35%.
However, all three had a significant increase when the coating level was 30%. Therefore,
30% of the coating level was further considered.
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5.2.2 Effects of formulation
The effect of net EC content on release time could be seen in Fig. 5.5. It was clear that
none of these three formulation powders met the requirement of a net EC weight of 6%.
However, when EC content was in the range of 40%, 60%, and 80%, if the EC content
was lower, and the curve shifted to the upper left of the graph (lower EC content and
longer release time). This also gave us the reason to believe that reducing the EC content
to 20% was likely to have better results.
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Figure 5.5 The effect of net EC content on release time. (Curing time: 3h)
According to the relationship between the coating level and the release time, a 30%
coating level could often bring about better result. In accordance with the premise (Net
EC<=6%), formulations containing 20% EC by weight were considered.
As a rule of thumb, 20% by weight of EC, 25% by weight of talc and 55% by weight of
lactose were first used for coating. The dissolution curve could be seen in Figure 5.6. The
SEM could be seen in Figure 5.7.
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Figure 5.6 The release profile of amino acid pellets. (Coating powder formulation:
20% EC, 25% talc and 55% lactose. Coating level: 30%. Curing time: 3h)

Figure 5.7 SEM of EC coated amino acid pellets. (Coating powder formulation: 20%
EC, 25% talc and 55% lactose. Coating level: 30%. Curing time: 3h)
The formulation of 20% EC, 25% talc and 55% lactose did not meet the requirements.
Under the premise that the EC content was 20%, the ratio of talc and lactose was adjusted.
The different ratios and release times could be seen in Fig. 5.8.
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Figure 5.8 The effect of talc content on release time
(Coating level: 30%. Curing time: 3h)
Under the premise that the EC content is 20%, the ratio of talc and lactose had a great
influence on the release time. In the case of 50% talc and 30% lactose, the release time
reached 150 minutes. However, this did not correspond to the weight ratio of 1:2 to 1:3
for the talc and lactose in the normal case. The amount of EC content was likely to have
an impact on the empirical formula. The SEM of amino acid production could be seen in
Fig. 5.9.

Figure 5.9 The SEM of EC coated amino acid pellets （Coating powder formulation:
20% EC, 50% talc and 30% lactose. Coating level: 30%. Curing time: 3h)
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5.2.3 Effects of the plasticizer-powder ratio
Under the precondition that both films were uniform and amino acid pellets were as moist
as possible, the ratio of plasticizer and powder represented the possibility of film
formation during the coating process. The higher this ratio was, the easier it was to form a
uniform film; the lower the ratio, the higher the amount of powder particles present on
the surface resulting in a brittle film.
According to the ratio of the amount of EC, powder formulations was divided into two
types. One is too much or too little EC. If EC content was too much, the powder stuck to
the surface more easily without forming a film, resulting in a more brittle film, which
required more plasticizers to make up for this shortcoming.
In the case where the coating level was approximately 30%. If EC content is too little, an
uneven film will form due to the lack of polymers, which could be compensated by
increasing the coating level. Therefore, the relationship could be seen in Figure 5.10.
Another situation is that the EC was at a suitable amount. The higher the EC content was
and more the plasticizers were provided, the easier to form a uniform film, which can be
seen in Fig. 5.11. Coating potential was defined as the product of the plasticizer-powder
ration and coating level for higher or lower EC content series formulation and as the
product of the plasticizer-powder ratio and net EC content for medium EC content series
formulation.
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Figure 5.10 The effect of the coating potential on the release time (EC content:80%)
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Figure 5.11 The effect of the coating potential on the release time
(EC content: 40% and 60%)
From the two figures above, it could be seen that when the EC content was 40% and 60%,
the release time was more related to the ratio of plasticizer and powder and the net EC
content. When the product of the ratio and the net EC content was about 3, the release
time was about 150 minutes, which satisfied our requirement.
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At the same time, when the EC content was 80%, the release time was related to the ratio
of plasticizer and powder and the coating level. When the product of the ratio and the
coating level was approximately 9, the release time could be made to be 150 minutes.
This conclusion could also be applied to the formulation of 20% EC. When the coating
level was 30%, the ratio of plasticizer to powder was 0.286 and the release time was 150
minutes. The product in this process was 8.6, which was about 9.

5.2.4 Effects of curing time
In dry powder coating technology, most polymers are thermoplastic materials. When the
curing temperature exceeds the glass transition temperature of the polymer, the
thermoplastic polymer forms a thin film. The curing process is critical to the uniformity
of the film. This process requires a certain amount of time.
At 55°C, curing results were shown in Fig. 5.12 with four intervals (0h, 1h, 2h, 3h). SEM
was used to demonstrate the effect of curing time on the film.

(A)

(B)
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Figure 5.12 SEM of EC coated amino acid pellets with different curing time
(Coating powder formulation: 20% EC, 50% talc and 30% lactose.
Coating level: 30%). (A) 0h, (B) 1h, (C) 2h, (D) 3h
As shown in the Figure 5.12, when the curing process started, at the 0h, there were many
particulates on the surface of the amino acid pellets, and the powder particles were
independent of each other and no film was formed. This resulted in a very uneven surface
of the amino acid pellets and some pores on the surface. At 1h, the powder particles
began to fuse with each other, but the amino acid surface was still not smooth enough and
consisted of some pores, and the particles were still somewhat independent of each other.
At the second hour, a film made of a polymer material was already visible, the powder
particles had already merged into one another, but there was still a small presence of
pores. In the third hour, there were few pores and the membrane was more uniform.
The release time of amino acid pellets with different curing time could be seen in Figure
5.13. From the SEM image, the films which had been cured for two or three hours had a
good homogeneity, so their release time was about 150 minutes. The release time of the
amino acid pellets with one hour of curing time was 135 minutes, and there were some
pores in the film. The surface of the amino acid pellets that had not undergone the curing
process were very uneven, so the release time was only 120 minutes. The curving process
could increase the release time of the amino acid pellets to a certain extent. However, due
to the curing time between each injection, the amino acid pellets have had a film and a
certain of release time before the curing process.
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Figure 5.13 The effect of curing time on release profile (Coating powder formulation:
20% EC, 50% talc and 30% lactose. Coating level: 30%)
As a product, appearance is also a very important factor. The appearance of different
curing time amino acid pellets can be seen in Figure 5.14.

(A)
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Figure 5.14 The appearance of EC coated amino acid pellets with different curing
time (Coating powder formulation: 20% EC, 50% talc and 30% lactose.
Coating level: 30%). (A) 0h, (B) 1h, (C) 2h, (D) 3h
The amino acid pellets that had not undergone the curing process were blue and off-white.
By increasing time, the blue color of the amino acid pellets became brighter and the
appearance became more and more appealing. Therefore, a curing period of three hours
was more commonly used.
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6

Scale-up Experiments for Amino Acid Pellets

6.1 Introduction
Ningbo Wesdon Powder Pharma Coatings Co., Ltd. is located in the Ningbo New
Material Innovation Zone of Ningbo National High-tech Zone, Zhejiang Province. As a
high-end entrepreneurship and innovation team in Ningbo, Wesdon Coating Technology
has obtained funding from the government's “3315 Plan” of 10 million yuan for the
promotion of efficient and environmentally friendly ultra-fine powder dry drug coating
technology and equipment.
At present, pharmaceutical companies generally adopt wet film coating technology to
coat solid pharmaceutical preparations. However, due to the requirement of heat, the
evaporation of organic solvents or water occupies a large portion of the total cost.
Additionally, to obtain a smooth and uniform coating surface, several hours or even days
are required for curing. Wesdon applied the ultra-fine powder electrostatic spraying
technology to pharmaceutical preparations for the first time, fundamentally solving the
limitations of wet coating, which is a huge innovation. The dry powder coating
technology sprays the micronized coating material on the surface of the drug and melts it
to form a uniform and dense functional coating. The project has successfully completed
the 50kg scale test. The dry coating technology, in comparison with wet coating, offers
the benefits of a simpler solvent treatment, lower energy consumption and lower costs.
Furthermore, the technology can potentially produce osmotic pumps and biological
products with antimicrobial coatings.

6.2 Objectives
The main purpose of this project is to scale up the coating process of 50g-scale sustained
release amino acid pellets to the scale of 800g.
First, amino acid pellets can be released slowly in water for two hours. Second, optimize
the coating process and reduce overall costs.
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6.3 Materials
Talc powder was from Bulk Pharmaceutical Chemical. Lactose (Tablettose® 80) was
bought from Meggle Pharma - Excipients & Technology. Ethyl cellulose (EC) was
bought from Xiaolun (Zhejiang) Pharmaceutical Machinery Co., Ltd. Triethyl citrate
(TEC) was from EMD Millipore Corporation (Germany).

6.4 Methods
6.4.1 Particle size reduction
In general, smaller diameter particles are more expensive than larger diameter particles.
In larger scale experiments, due to more demand for particles and taking into the factor of
cost, particles with large particle sizes are often purchased, and the required small size
particles are obtained after jet mill treatment. A typical pilot-scale jet mill is shown in
Figure 6.1, which can smash 1.5 kg 300 microns ethyl cellulose (EC) to less than 50
microns EC in one hour.

Figure 6.1 The schematic of jet mill

6.4.2 Powder mixing
In the coating of amino acid pellets of 50g scale, it was usually necessary to dispose 20g
of coating powder, so a small stirrer could meet the demand. However, for the 800g-scale
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amino acid pellets coating experiment, a larger V-shaped stirrer (shown in Fig. 6.2) is
used to ensure complete mixing for the larger batch size.

Figure 6.2 The schematic of V-shaped stirrer

6.4.3 In-vitro drug release testing
In-vitro drug release profiles of the coated samples were tested by the United States
Pharmacopeia (USP) apparatus (Apparatus 2, paddle; TDTF ZRS-8GD, Tianjin, China).
For the EC coated amino acid pellets, the drug release medium is 1000 mL of pure water
maintained at 37°C with a 50 RMP paddle rotation speed.
In this process, 10 mL of the sample was collected using a 10mL syringe over a certain
period, and 10 mL of fresh medium (pure water) was immediately supplemented. After
10 mL of the sample was filtered, it was analyzed with a UV-Visible spectrophotometer.
The maximum absorption wavelength of the analyzed component of the amino acid pellet
was 194 nm.
The drug dissolution profiles of amino acid pellets can be seen in Figures 3.1. The curve
is used to determine the concentration of the sample obtained from the dissolution test.
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Figure 6.3 Standard curve of amino acid pellets
After the creation of the standard curve of amino acid pellets, a precision test, accuracy
test and a stability test are required for the acceptability validation of the application of
UV-vis spectrophotometer that is used for the measurement and analysis of the drug
release from amino acid pellets. The method of processing is the same as that in section
3.7.2.

6.5 Scale-up experiments of plasticizer-assisted powder
coating of amino acid pellets
6.5.1 Apparatus
Compared with the small rotating coating pan in the Western University laboratory,
Wesdon's large-scale rotating coating pan has been greatly improved. Generally, the
rotating coating pan is heated by gas, and hot air enters the incubator from the upper part
and exits from the lower part of the incubator. The liquid plasticizer spray system
includes a metering pump and an atomizing nozzle. The powder spraying system includes
a nozzle and a feeder. The atomizing nozzle and the powder nozzle are placed in the
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middle of the coating pan. The entire coating pan is nearly cylindrical with oppositely
oriented edges inside, which promotes the rolling of the pellets. The schematic of rotating
coating pan is shown in Fig. 6.4.
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Figure 6.4 The schematic of rotating coating pan for scale-up experiments.
(A) Liquid nozzle. (B) Powder nozzle. (C) Air inlet. (D) Air outlet.
(E) Powder feeder. (F) Air pump. (G) Metering pump.
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6.5.2 Experimental procedures
The process of coating the sustained release amino acid pellets with a rotating coating
pan is divided into four parts including: preparing the coating powder, preheating the
pellets and equipment, concurrently spraying the plasticizer and the coating material and
curing.
The first step is to prepare the coating material for the pellets. Ethyl cellulose (EC),
lactose, talc, and certain pigments are mixed into a uniform formula until no
agglomeration or color difference occurs. Relative to the 50g scale experiment, the 800g
scale experiment requires the use of special equipment (V-shaped stirrer) for mixing.
Various materials were placed in a V-shaped stirrer and mixed at a constant rate for 15
minutes before being removed.
The second step is to put 800g of amino acid pellets into the rotating coating pan, set a
certain intake temperature (to ensure the temperature of the outgoing gas exceeds the
glass transition temperature) and rotate the coating pan at a slow speed.
Next, the rotational speed of the coating pan is increased to avoid adhesion of amino acid
pellets and pan. Since the total volume of amino acid pellets is large, they will be stacked
in the pan. Due to this, the liquid plasticizer and coating the powder are to be sprayed
concurrently to promote a consistent coat among the pellets. The two nozzles are to be
controlled in the central of the coating pan, which avoids the polymerization of
plasticizers and coating powders in the free zone of the pan. The speed is reduced for 10
minutes then the third step is to be repeated.
The curing step begins when there is a sufficient amount of coating material on the
surface of the amino acid pellets. To prevent adhesion, this step usually requires the
addition of a certain amount of talc. Due to the stack of amino acid pellets, gravity
promotes the curing of the pellets. Therefore, the 800g amino acid pellets curing process
requires only one hour.
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6.5.2 Optimization
Effect of powder efficiency
In small-scale experiments, powder efficiency is often overlooked. To some extent, some
materials are abused to get the best result, however, in the industrial production, the cost
is the key factor that is taken into consideration. Therefore, the efficiency of powdered
products must be optimized first.
To completely bind the liquid plasticizer and coating powder to the amino acid pellets,
the coating pan has a higher linear velocity, a greater atomization degree of the liquid
plasticizer, and a larger spray rate of the coating powder. These factors can cause a
portion of the amino acid pellets to fall out of the coating pan. A portion of the liquid
plasticizer and the coating powder flow out with the gas in the incubator. In order to
improve this deficiency, a plastic pad was installed on the inlet of the coating pan and the
plastic pad was fixed with the nozzle. The improved rotating pan is shown in Fig. 6.5.

(C)
(B)
(E)
(H)

(A)

(G)

(D)

(F)

Figure 6.5 The schematic of improved rotating coating pan for scale-up experiments.
(A) Liquid nozzle. (B) Powder nozzle. (C) Air inlet. (D) Air outlet. (E) Powder feeder.
(F) Air pump. (G) Metering pump. (H) Plastic pad.
According to the same procedure, 240g of the coating material and 60g of the liquid
plasticizer were sprayed onto 800g of the amino acid pellets using a covered coating pan
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and a coverless coating pan, respectively. The powder efficiency is shown in Fig. 6.6, and
the final product is shown in the Fig. 6.7.
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Figure 6.6 Powder efficiency of coating pan with and without cover
(Plasticizer: 60g).

(A)
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Figure 6.7 The appearance of EC coated amino acid pellets (With after curing).
(A) Coating pan with cover. (B) Coating pan without cover
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Effect of the amount of plasticizer
As mentioned previously, the ratio of plasticizer and powder represents the possibility of
film formation during the coating process. The higher this ratio is, the easier it is to form
a uniform film; the lower the ratio, the higher the amount of powder particles present on
the surface resulting in a brittle film.
For this experiment, the surface of 800g of amino acid pellets needs to be sprayed with
240g of the coating material, corresponding to a 30% net coating level. Therefore,
different amounts of plasticizers were used to find the most suitable release time. Under
the same experimental procedure, the surface of the amino acid particles is uniformly
sprayed with plasticizer at a constant speed. The weight of the liquid plasticizer was
chosen as 60g, 80g and 100g. The corresponding dissolution time is shown in the Fig. 6.8,
and the appearance of the corresponding product is shown in the Fig. 6.9.
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Figure 6.8 The effect of the amount of plasticizer on release time (With after curing).
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Figure 6.9 The appearance of EC coated amino acid pellets with different amounts
of plasticizer (With after curing). (A) 60g. (B) 80g. (A) 100g.
Effect of the plasticizer flow rate
When 80g of liquid plasticizer is used, the amino acid pellets have the longest release
time. However, the 90 minutes release time does not meet the 120 minutes release time
requirement. It is noted that during spraying, more liquid plasticizer will benefit the
formation of a dense film on the surface of the amino acid pellets, however, too much
plasticizer will cause the amino acid pellets stick together, resulting in a reduction of the
release time. Therefore, an improved method is spray the liquid plasticizer at a lower
flow rate while the total weight of the liquid plasticizer is unchanged. Using 60g of liquid
plasticizer, the original and post-improvement release times are shown in Figure 6.10.
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Figure 6.10 The effect of the way of spraying plasticizer on release time
(Plasticizer:60g. With after curing).
Effect of after curing
In general, during the production of dry powder coated solid preparations, the solid
preparations need to be cured in an incubator for a certain period in addition to the curing
process in the coating pan. In the small-scale experiment, there was no significant
difference between the amino acid pellets that had undergone the incubator curing
process and the amino acid pellets that had not undergone the curing process in the
incubator. In this experiment, given the 800g of amino acid pellets and 240g of coating
powder, two release profiles of amino acid pellets using 60g liquid plasticizer and 80g
liquid plasticizer are shown in Fig. 6.11.
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Figure 6.11 The effect of curving on release profile
(A): 60 g plasticizer (B): 80g plasticizer
For amino acid pellets using 60g plasticizer, the release speed was accelerated after the
curing process in the incubator. For amino acid granules using 80g plasticizer, the curing
process in the incubator retarded the release rate.
A reasonable explanation is that when more liquid plasticizer was used, the amino acid
pellets were sufficiently moist and the curing process in the incubator favored a denser
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film on the surface of the pellets. However, if there was less liquid plasticizer, there
would be some pores on the surface of the amino acid pellets, which would increase the
cracks of the film to a certain extent during the curing process in the incubator, thereby
reducing the release time. The appearance of the original amino acid pellets with 60g
plasticizer and the amino acid pellets with 60g plasticizer that had undergone curing in
the incubator can be seen in Figure 6.12. After the curing process, the color of the amino
acid pellets became lighter and the film was relatively more fragile.

(A)

(B)

Figure 6.12 The appearance of EC coated amino acid pellets with 60g plasticizer.
(A) With curing. (B) Without curing
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Conclusions

Coating products based on dry powder coating technology platform were produced
successfully. Immediate release of ginseng chewable tablets using electrostatic powder
coating technology ensures that the product has a certain degree of wear resistance and
aesthetics with an immediate release in 5 minutes. The sustained release amino acid
pellets using the plasticizer-assisted powder coating technique achieved a sustained
release in 2-3 hours.
For ginseng chewable tablets with immediate release coating, in the process of tableting,
for the lubricity of the mixed powder and the hardness of the chewable tablets, different
kinds of the tableting materials with various ratio are investigated. The optimal tableting
formulation was found to be 40%wt of ginseng powder, 58%wt of mannitol and 2%wt of
magnesium stearate, where sufficient lubricity of the mixed powder can be achieved, and
the tablet hardness was stabilized at 60N.
In the process of coating immediate release ginseng chewable tablets, coating materials,
coating temperature, curing time and coating level were used to investigate. The best
conditions were found to be using HPC as a coating material, PEG 400 as a plasticizer,
coating at 50°C and curing for 3 hours. By SEM micrographs, a uniform firm was formed
on the surface of chewable tablets with 2% and 3% coating levels. In the case of
simulated chewing, immediate release of ginseng chewable tablets achieved complete
release within 7 minutes. As a product, the immediate release ginseng chewable tablets
with coating have a good appearance and considerable wear resistance.
For amino acid pellets with sustained release coating, SEM micrographs show that pellets
with higher coating levels exhibit a better film smoothness. With a given formulation, the
in-vitro drug release test showed pellets having a higher level of the coating can have a
longer sustained release time. In addition, the composition of EC in the coating material
is essential for the sustained release coating process. As a product, sustained release

75

amino acid pellets with a longer curing time (3h) have a better smoothness from SEM
micrographs, and at the same time as a commodity, have a better appearance.
In the 800g-scale experiment of sustained release amino acid pellets, for a given net
coating level of 30%, 80g liquid plasticizers can be used, the plasticizer flow rate can be
slower. The produced amino acid pellets of this coating level are placed in an incubator
for a certain period to meet the two-hour release time requirement.
In summary, the dry powder coating technology can be well applied to the immediate
release ginseng chewable tablets and sustained release amino acid pellets. Those
laboratory studies provided new opportunities for additional potential commercial
applications for dry powder coating technology.
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Appendices
Appendix A. Example of Error analysis
It is necessary to ensure that the experimental error is within a certain confidence interval.
Thus, some typical experiments are selected for analysis.
The example of the effect of coating level on hardness of ginseng chewable tablets with
error bars can be seen in Fig. A.1. These results are repeated for three times. For the
ginseng chewable tablets of 2% coating level, at 3 minutes, the cumulative release data
for three experiments is 70.2, 71.3 and 69.4, respectively. The mean of these three data is
70.3 and the standard deviation of the data is 0.95. In addition, these three data are within
the 95% confidence interval. Thus, the data is acceptable.
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Figure A.1 The effect of coating level on release time (curing time: 3h)
The error bars of the effect of curing time on release profile for amino acid pellets
(Coating powder formulation: 20% EC, 50% talc and 30% lactose. Coating level: 30%)
are shown in Fig. A.2. These results are repeated for three times. For the ginseng
chewable tablets with 0h curing time, at 50 minutes, the cumulative release data for the
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three experiments are 61.4, 62.6 and 61.8, respectively. The mean of these three data is
62.3 and the standard deviation of the data is 0.76. In addition, these three data are within
the 95% confidence interval. Thus, the data is acceptable.
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Figure A.2 The effect of curing time on release profile (Coating powder formulation:
20% EC, 50% talc and 30% lactose. Coating level: 30%)
These analyses show that the experimental errors of this type experiments are small.
Other similar experiments can be handled in the same way.
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